San Francisco, CA
Ncardia is heading to NorCal SOT this May in South San Francisco, and we’re looking forward to a day of insightful discussions on nonclinical safety strategies for new modalities. Hosted at Genentech, this event offers a great opportunity to hear from industry leaders, explore new research, and connect with peers.
With our expertise in iPSC-based models for drug discovery and safety testing, we’re excited to exchange ideas on how advanced cellular models are shaping the future of nonclinical safety.
If you're passionate about predictive safety testing and new approaches in the field, we'd love to chat! Whether over a talk, a poster session, or a coffee at the networking reception, let's discuss how we can push innovation forward together. Join us in South San Francisco—click below to schedule a meeting with our team.
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.